28108302|t|Biomarkers associated with clinical manifestations in Fabry disease patients with a late-onset cardiac variant mutation
28108302|a|Fabry disease is a lysosomal storage disorder with an incidence of 1:1600 for the late-onset IVS4+919G>A cardiac variant mutation in Taiwan. Signs and symptoms of this cardiac variant include left ventricular hypertrophy, mitral insufficiency and/or arrhythmias. The search for biomarkers that might predict the clinical outcomes and guide treatment options is important. We thus investigated relationships between Fabry disease biomarkers (such as globotriaosylceramide (Gb3), globotriaosylsphingosine (lyso-Gb3)/related analogues) and age, gender, enzyme activity, clinical manifestations and severity of the disease in these patients. Urine and plasma biomarkers were analyzed using tandem mass spectrometry. A large cohort of 191 adult and pediatric Fabry patients carrying the IVS4+919G>A mutation was studied. Some patients were members of the same family. Our results show that the plasma lyso-Gb3 level, and urinary analogue levels of lyso-Gb3 at m/z (+16), (+34), and (+50) adjusted for gender and age had a positive association with the left ventricular mass index, and/or the Mainz Severity Score Index. It might thus be of particular interest to monitor children with high levels of these biomarkers, as part of a longitudinal study in order to determine if the excretion profile at a young age is predictive of the outcomes of disease severity in adulthood.
28108302	0	10	Biomarkers	T201	C0005516
28108302	11	26	associated with	T080	C0332281
28108302	27	50	clinical manifestations	T033	C0243095
28108302	54	67	Fabry disease	T047	C0002986
28108302	68	76	patients	T101	C0030705
28108302	84	94	late-onset	T079	C4025592
28108302	95	102	cardiac	T082	C1522601
28108302	103	110	variant	T080	C0205419
28108302	111	119	mutation	T045	C0026882
28108302	120	133	Fabry disease	T047	C0002986
28108302	139	165	lysosomal storage disorder	T047	C0085078
28108302	174	183	incidence	T081	C0021149
28108302	202	212	late-onset	T079	C4025592
28108302	213	224	IVS4+919G>A	T028	C0678941
28108302	225	232	cardiac	T082	C1522601
28108302	233	240	variant	T080	C0205419
28108302	241	249	mutation	T045	C0026882
28108302	253	259	Taiwan	T083	C0039260
28108302	261	279	Signs and symptoms	T184	C0037088
28108302	288	295	cardiac	T082	C1522601
28108302	296	303	variant	T080	C0205419
28108302	304	311	include	T052	C2700399
28108302	312	340	left ventricular hypertrophy	T047	C0149721
28108302	342	362	mitral insufficiency	T046	C0026266
28108302	370	381	arrhythmias	T033	C0003811
28108302	398	408	biomarkers	T201	C0005516
28108302	420	427	predict	T078	C0681842
28108302	432	440	clinical	T080	C0205210
28108302	441	449	outcomes	T080	C0085415
28108302	460	469	treatment	T061	C0087111
28108302	481	490	important	T080	C3898777
28108302	500	512	investigated	T169	C1292732
28108302	513	526	relationships	T080	C0439849
28108302	535	548	Fabry disease	T047	C0002986
28108302	549	559	biomarkers	T201	C0005516
28108302	569	590	globotriaosylceramide	T109	C0061338
28108302	592	595	Gb3	T109	C0061338
28108302	598	622	globotriaosylsphingosine	T109	C0082711
28108302	624	632	lyso-Gb3	T109	C0082711
28108302	642	651	analogues	T104	C0243071
28108302	657	660	age	T032	C0001779
28108302	662	668	gender	T032	C0079399
28108302	670	685	enzyme activity	T044	C0243102
28108302	687	710	clinical manifestations	T033	C0243095
28108302	715	723	severity	T080	C0439793
28108302	731	738	disease	T047	C0012634
28108302	748	756	patients	T101	C0030705
28108302	758	763	Urine	T031	C0042036
28108302	768	774	plasma	T031	C0032105
28108302	775	785	biomarkers	T201	C0005516
28108302	791	799	analyzed	T062	C0936012
28108302	806	830	tandem mass spectrometry	T063	C0599748
28108302	834	839	large	T081	C0549177
28108302	840	846	cohort	T098	C0599755
28108302	854	859	adult	T100	C0001675
28108302	864	873	pediatric	T080	C1521725
28108302	874	879	Fabry	T047	C0002986
28108302	880	888	patients	T101	C0030705
28108302	889	897	carrying	T052	C0206243
28108302	902	913	IVS4+919G>A	T028	C0678941
28108302	914	922	mutation	T045	C0026882
28108302	927	934	studied	T062	C2603343
28108302	941	949	patients	T101	C0030705
28108302	955	962	members	T099	C0086282
28108302	975	981	family	T099	C0015576
28108302	1009	1015	plasma	T031	C0032105
28108302	1016	1024	lyso-Gb3	T109	C0082711
28108302	1025	1030	level	T080	C0441889
28108302	1036	1043	urinary	T080	C1524119
28108302	1044	1052	analogue	T104	C0243071
28108302	1053	1059	levels	T080	C0441889
28108302	1063	1071	lyso-Gb3	T109	C0082711
28108302	1103	1111	adjusted	T169	C0456081
28108302	1116	1122	gender	T032	C0079399
28108302	1127	1130	age	T032	C0001779
28108302	1137	1145	positive	T033	C1514241
28108302	1146	1157	association	T080	C0439849
28108302	1167	1194	left ventricular mass index	T033	C0243095
28108302	1207	1227	Mainz Severity Score	T081	C0457451
28108302	1228	1233	Index	T081	C1637833
28108302	1266	1274	interest	T041	C0543488
28108302	1278	1285	monitor	T058	C0150369
28108302	1286	1294	children	T100	C0008059
28108302	1300	1304	high	T080	C0205250
28108302	1305	1311	levels	T080	C0441889
28108302	1321	1331	biomarkers	T201	C0005516
28108302	1346	1364	longitudinal study	T062	C0023981
28108302	1394	1403	excretion	T039	C0221102
28108302	1404	1411	profile	T169	C2003903
28108302	1417	1426	young age	T033	C4061789
28108302	1430	1440	predictive	T080	C0681890
28108302	1448	1456	outcomes	T169	C1274040
28108302	1460	1467	disease	T047	C0012634
28108302	1468	1476	severity	T080	C0439793
28108302	1480	1489	adulthood	T079	C0700597